BBP-711 is under clinical development by Cantero Therapeutics and currently in Phase I for Primary Hyperoxaluria Type I. According to GlobalData, Phase I drugs for Primary Hyperoxaluria Type I have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BBP-711’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BBP-711 is under development for the treatment of primary hyperoxaluria type 1 and recurrent kidney stone formers (frequent stone formers (FSF)). The drug candidate is administered through oral route as suspension. It acts by targeting glycolate oxidase (GO).
Cantero Therapeutics overview
Cantero Therapeutics formerly Orfan Biotech, a subsidiary of BridgeBio Pharma Inc, develops novel small-molecule therapy of glycolate oxidase (GO) for the treatment hyperoxaluria diseases. Orfan Biotech is headquartered in San Francisco, California, the US.
For a complete picture of BBP-711’s drug-specific PTSR and LoA scores, buy the report here.